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brovascular accidents and death. The expected costs were cal-
culated for 2005 from the perspective of the UK NHS. Each
event was associated with a transient decrement in health-related
utility due to recurrent symptoms while waiting for a repeat
intervention and to pain and distress of events or further inter-
ventions, relative to a baseline asymptomatic coronary heart
disease value based on the ARTS and SoS trials. A probabilistic
sensitivity analysis was undertaken. RESULTS: Although the
price premium of Endeavor is above £500, the total cost of
Endeavor treatment was only slightly higher at ﬁve years than
Driver (£6094 vs. £6058) due mainly to the reduced need for
revascularisations in the ﬁrst year. Endeavor was also associated
with QALY gains (0.0053 per patient), and therefore had an
incremental cost-effectiveness ratio of ~£6700/QALY. The prob-
ability of Endeavor being cost-effective at a threshold of
£30,000/QALY was 58%. CONCLUSIONS: This exploratory
analysis shows the Endeavor DES to be cost-effective. Results of
long-term trials are awaited to conﬁrm model predictions.
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OBJECTIVE: To determine the cost-effectiveness (CE) from the
Belgian societal perspective of anticoagulation with bivalirudin
vs. heparin + glycoprotein inhibitors (GPIIb/IIIa) in patients
undergoing percutaneous coronary intervention (PCI).
METHODS: Efﬁcacy data were taken from REPLACE-2, EPIS-
TENT and ESPRIT trials which documented probabilities of PCI
outcomes: death, myocardial infarction, urgent revasculariza-
tion, and major/minor bleedings according to TIMI deﬁnition.
Costs data were drawn from Belgian literature except for drug
costs which were valued using REPLACE-2 actual dosages and
ofﬁcial Belgian tariffs. We considered unfractionated (UFH) and
low-molecular weight (LMWH) heparins. Abciximab was the
only GPIIb/IIIa considered as it is the only one indicated for PCI
in Belgium. A 30-day time frame analytical model was developed
from an original model by The Swedish Institute for Health Eco-
nomics (IHE), to estimate the incremental costs per life year
gained (LYG). Costs and LYG were discounted at 3.0% per
annum. In the base case analysis, GPIIb/IIIa was given in 27.5%
of the patients receiving heparin (consensus estimate between the
Belgian Working Group in Interventional Cardiology and expert
opinions). RESULTS: Giving bivalirudin to the average patient
undergoing PCI in Belgium resulted in extra 0.0794LYG and
€90.1 vs. UFH (incremental cost-effectiveness ratio (iCER) =
€1134.8/LYG). LMWH was dominated. A threshold analysis,
varying from 0% to 100% the percentage of patients in the
heparin branches who receive additional GPIIb/IIIa, revealed
that when this percentage is above 34%, bivalirudin dominates
both heparin strategies. When no patient at all was given addi-
tional GPIIb/IIIa, the iCER vs. UFH was €3933.3/LYG. Other
variables were much less sensitive. CONCLUSION: Our analy-
sis suggests that the use of bivalirudin during PCI is a cost-effec-
tive alternative to the current approach of heparin + GP IIb/IIIa
in the Belgian health care setting. The percentage of patients
given GPIIb/IIIa with heparin is the key factor driving the iCER
of bivalirudin.
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OBJECTIVES: Primary bare metal stenting and abciximab infu-
sion are currently considered the best available reperfusion strat-
egy for acute ST-segment elevation myocardial infarction
(STEMI). Sirolimus eluting stents (SES), compared to bare metal
stent (BMS), greatly reduce the incidence of binary restenosis and
target vessel revascularisation (TVR), but their use on a routine
basis results in a signiﬁcant increase in medical costs. With
current European list prices, the use of tiroﬁban (TIRO) instead
of abciximab (AB) would save enough money to absorb the dif-
ference in cost between SES and BMS. The STRATEGY study
examined the safety and efﬁcacy of tiroﬁban and SES vs. AB and
BMS in STEMI patients. To evaluate the short- and medium-term
economic impact of the STRATEGY combination, namely TIRO
+ SES versus current golden standard of treatment, AB + BMS.
METHODS: A medium-term (one year or 8 months) decision
analytic model was developed to conduct a cost-effectiveness
analysis using a cost per survival. The perspective of the model
was that of Italy. Clinical outcomes (mortality, myocardial
infarction (MI), revascularization (Revasc) and major cardiac
events (MACE) were based on the ﬁnal results of the STRAT-
EGY study. Costs were obtained from Italian sources for device
and hospitalization data (€2004). Total expected costs and out-
comes for TIRO + SES versus AB + BMS were compared. The
robustness of the results was tested in a sensitivity analysis.
RESULTS: Clinical outcomes were lower for TIRO + SES when
compared to AB + BMS for mortality (0.079 vs. 0.089), MI
(0.068 vs. 0.089), Revasc (0.067 vs. 0.197) and MACE (0.214
vs. 0.377). The average overall cost of TIRO + DES (€23,674)
was less expensive than that of AB + BMS (€24,274) with an
incremental difference of €600. One-way sensitivity analysis
indicated the model was sensitive to the unit cost of AB with a
threshold value of €338. CONCLUSIONS: TIRO + SES resulted
to be the dominant strategy.
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OBJECTIVE: To compare treatment patterns, speciﬁcally per-
sistence and compliance, among postmenopausal osteoporotic
women treated with daily or weekly bisphosphonates.
METHODS: Data were obtained from a US managed care data-
base. The study cohort included women with an osteoporosis
diagnosis (ICD-9 code 733.0) followed by a prescription for
alendronate 10mg (daily) or 70mg (weekly), risedronate 5mg
